Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Crystal clear - Part II: the role of uric acid in cardiorenal disease

Title: Crystal clear - Part II: the role of uric acid in cardiorenal disease
Authors: Borghi C; Fogacci F; Cicero AFG.
Contributors: Borghi, C; Fogacci, F; Cicero, Afg.
Publication Year: 2025
Collection: IRIS Università degli Studi di Bologna (CRIS - Current Research Information System)
Subject Terms: Coronary artery disease; Heart failure; Hypertension; Peripheral artery disease; SGLT2 inhibitor; Stroke; Uric acid; Xanthine oxidase inhibitors
Description: Building on the foundational mechanistic and epidemiological knowledge from Part I, this second part of the review further unpacks the cardiovascular implications of abnormalities in serum levels of uric acid (UA). With a focus on hypertension, coronary artery disease (CAD), heart failure (HF), stroke, and peripheral artery disease (PAD), we provide a nuanced synthesis of how elevated serum UA influences disease risk and clinical outcomes. We describe mechanistic pathways including endothelial dysfunction, vascular smooth muscle proliferation, oxidative stress, inflammation, and renin-angiotensin system activation. Large cohort studies demonstrate linear or U-shaped relationships between serum UA (SUA) and cardiovascular events, with risk often appearing below conventional hyperuricemia thresholds. We also analyze interventional evidence for UA-lowering treatments such as xanthine oxidase inhibitors, urate transporter 1 (URAT-1) inhibitors and sodium-glucose transport protein 2 (SGLT2), highlighting context-dependent benefits in patients with hypertension or heart failure, both with and without preserved ejection fraction. Importantly, we discuss sex differences, kidney function influence, and the U-shaped association seen in men. Finally, we argue that SUA should be integrated into cardiovascular risk stratification, potentially serving as both a biomarker and a therapeutic target, while recognizing the need for personalized approaches based on comorbidities and biochemical profiles. This completes the two-part series by bridging mechanistic insights with practical clinical implications.
Document Type: article in journal/newspaper
File Description: ELETTRONICO
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/41111035; info:eu-repo/semantics/altIdentifier/wos/WOS:001633892900004; volume:142; firstpage:1; lastpage:13; numberofpages:13; journal:EUROPEAN JOURNAL OF INTERNAL MEDICINE; https://hdl.handle.net/11585/1039385; https://www.sciencedirect.com/science/article/pii/S0953620525004315
DOI: 10.1016/j.ejim.2025.106554
Availability: https://hdl.handle.net/11585/1039385; https://doi.org/10.1016/j.ejim.2025.106554; https://www.sciencedirect.com/science/article/pii/S0953620525004315
Rights: info:eu-repo/semantics/openAccess ; license:Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY) ; license uri:iris.PUB15
Accession Number: edsbas.D2CC97E
Database: BASE